PEPTIDES·INDEX
79 peptides463 listingsUpdated 4h agoBuild My Stack
Library

Testosterone Enanthate

Testosterone esterified with enanthate, an oil-based injectable also given subcutaneously. Reference entry for the calculators, not tracked for price.

Reference compound, not sold here. Profile for research context only.

StatusFDA-approved · Rx
Class17β-heptanoate (C7) ester of testosterone; oil-depot androgen for IM injection or SC autoinjector; Schedule III controlled substance in the US
RouteIntramuscular · Subcutaneous

Overview

Testosterone enanthate is the heptanoate ester of testosterone: the parent hormone with a straight seven-carbon fatty-acid chain on its 17β-hydroxyl, dissolved in sesame oil for slow release from a depot. This is a reference entry, not a product the index tracks — no enanthate listings or prices appear here; it exists so the parent page's half-life and interval questions can name the ester. It is the only testosterone ester with an approved subcutaneous route in the US: generic Testosterone Enanthate Injection USP (Hikma, Eugia) is for deep intramuscular use, and Xyosted (Antares Pharma) is a once-weekly subcutaneous autoinjector. Both are indicated for replacement in males with hypogonadism; the IM label adds delayed puberty and palliation of inoperable mammary cancer in women. Schedule III controlled substance; prohibited at all times under WADA class S1. Nothing here is dosing or treatment advice.

Chemistry#

C26H40O3, 400.6 g/mol (the Xyosted label prints 400.59), CAS 315-37-7, PubChem CID 9416. The chain is heptanoate — straight, C7 — one carbon shorter than cypionate's ring-containing ester, so about 72% of the mass is testosterone (288.4/400.6, arithmetic from the two sourced weights). The steroid core is unchanged; the chain only sets release from the oil.

Formulation#

The IM generic is 200 mg/mL in sesame oil with 5 mg/mL chlorobutanol as preservative, labelled "For Intramuscular Use ONLY", deep gluteal. Its reference product, Delatestryl, was NDA 009165, approved 1953-12-24 and now discontinued. Labelled replacement dosing is 50–400 mg every two to four weeks. Xyosted is a 50, 75 or 100 mg per 0.5 mL single-dose autoinjector whose only listed inactive ingredient is sesame oil; the label's starting dose is 75 mg subcutaneously in the abdomen once a week, adjusted on a trough drawn seven days after a dose once six weeks have passed. It was approved as NDA 209863 on 2018-09-28. Note that both US products are sesame-oil preparations, whereas the textbook half-life below refers to a castor-oil one.

History#

Nieschlag records that the longer-acting enanthate appeared from the mid-1950s and remained the major testosterone preparation for half a century, succeeding the short-acting propionate. Delatestryl's 1953-12-24 FDA approval was a new-active-ingredient approval, now held by Endo and discontinued, with generics continuing. The first subcutaneous enanthate product, Xyosted, followed in 2018.

How it works

The ester is inert until hydrolysed; what acts is testosterone, so mechanism — androgen-receptor agonism directly and via dihydrotestosterone, feedback suppression of pituitary LH and of spermatogenesis — is the parent's and is described on the testosterone profile.

Pharmacokinetics#

No US label states an enanthate half-life. The Hikma label says only that testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase, and that reported half-lives of testosterone itself vary from 10 to 100 minutes. The Xyosted label gives a median time to peak of 11.9 hours (range 5.8–168.7 h) and steady state by week 6, but no half-life; the FDA clinical pharmacology review for NDA 209863 contains none either. The route-specific primary figures used in the numeric entry come from the sponsor's single-dose SC study NCT02233751 (12 healthy men, QuickShot autoinjector, six per dose group): total-testosterone half-life 131.75 ± 28.05 h at 200 mg and 261.73 ± 99.04 h at 50 mg, with the enanthate analyte itself at 133.00 ± 67.85 h at 200 mg and not calculable at 50 mg. The dose-dependence is the tell: these are apparent, absorption-limited (flip-flop) half-lives shaped by depot release and, in healthy men, by their own baseline — not an elimination constant. The familiar ~4.5 days for IM injection (mean residence time 8.5 days) is a textbook value from the Nieschlag/Behre Andrology preparations table for a castor-oil preparation, not a primary paper; we show it as text only. A secondary database figure of 7–9 days is not used.

Evidence

Every study below used testosterone enanthate specifically. Male contraception: the WHO Task Force trials gave 200 mg IM weekly — in the 1990 Lancet study 157 of 271 men became azoospermic, with one pregnancy in 1,486 months of exposure; the 1996 Fertility and Sterility study enrolled 399 men in 15 centres. Supraphysiologic dosing: Bhasin's 1996 NEJM trial gave 43 men 600 mg weekly for 10 weeks with or without resistance exercise. Dose-response: Bhasin 2001 suppressed endogenous production with a GnRH agonist and gave 25, 50, 125, 300 or 600 mg weekly for 20 weeks; fat-free mass rose with dose. Subcutaneous program: a 52-week dose-adjusted study (Kaminetsky 2019) and a 26-week safety study underpin Xyosted; its label reports that 135 of 150 hypogonadal men (90%) had an average concentration within 300–1,100 ng/dL at week 12. The IM label's other indications — delayed puberty and palliation of metastatic breast cancer — are labelled uses, not trials reported here.

Anecdotal reports community-reported

What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.

  • Interchangeable with cypionatecommonly reported

    When a pharmacy substitutes enanthate for prescribed cypionate, the near-unanimous advice is to use it: users say the two are functionally identical for weekly, every-other-day or daily sub-Q dosing and rotate between them. Dissenters mention enanthate arriving at higher concentrations that irritate more, and a handful prefer the 'bite' of cypionate.

  • Post-injection pain, lumps and the carrier oila sizeable minority

    Enanthate is the long ester most often blamed for post-injection pain: users describe lumps and swelling that make sitting or lateral raises painful, usually blamed on a bad batch, solvent-heavy carrier oil, too much volume per site or a half-inch needle missing the muscle. Reported fixes are a longer needle, a larger muscle, massaging or warming the oil, smaller shots, and switching brand or to cypionate.

  • 500 mg/week first cyclecommonly reported

    First-cycle reports of 500 mg/week pinned twice weekly for 16 weeks describe roughly 30 lb of scale weight, large strength jumps and higher libido, with total testosterone far above the reference range. Puffy nipples and water retention around week eight are commonly reported and managed with an aromatase inhibitor; monthly blood donation and cardio are mentioned as mitigation.

  • Early weeks: fatigue, flatness and 'placebo'commonly reported

    Two weeks in, some users report fatigue and no training boost on 125 mg twice weekly, and the common reply is that nothing real is felt before four to six weeks. On daily low doses others describe an early surge of energy and libido that fades into an irritable afternoon dip by week six, which replies attribute to natural production shutting down rather than the ester wearing off.

  • Acne and shedding blamed on enanthate specificallyoccasionally reported

    A few users say enanthate gives them cystic back acne or more shedding than cypionate despite identical dose, frequency, carrier and estradiol, and switched for good; others call this a dirty batch rather than the ester. Most who have used both report no difference at all.

Safety

Class risks — erythrocytosis, androgenic skin effects, gynecomastia, fluid retention, suppressed spermatogenesis, mood change, venous thromboembolism, and the abuse syndrome — are the parent's and are set out on the testosterone profile. Specific to this ester's products: Xyosted carried a boxed warning for blood-pressure increases, which the current label's Highlights list as removed in 03/2025, while section 5.4 still states it is not recommended in uncontrolled hypertension. Both US products are sesame-oil preparations, and the IM generic adds chlorobutanol, so sesame allergy and preservative sensitivity are formulation-specific considerations. The IM label's indications include women 1–5 years postmenopausal with metastatic breast cancer, the only labelled testosterone use in women among these esters. Safety and efficacy in age-related hypogonadism are not established. Prescription-only Schedule III; the safety score of 3 mirrors the parent's and would be lower for unlabeled or underground products.

Reported side effects

Reported in published literature and user reports. Not a complete list, and not medical advice.

  • Class effects of testosterone — erythrocytosis, acne, gynecomastia, fluid retention, suppressed spermatogenesis, mood changes, venous thromboembolism (see the testosterone profile)
  • Blood-pressure increases — Xyosted carried a boxed warning until 03/2025 and remains not recommended in uncontrolled hypertension
  • Injection-site reactions from the oil depot (IM) or weekly abdominal SC injection
  • Hypersensitivity to the vehicle — sesame oil in both US products; chlorobutanol preservative in the IM generic
  • Abuse and dependence (label section) at doses higher than recommended

If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.

Cautions discuss with a clinician

Use caution or avoid if
  • Known or suspected carcinoma of the prostate, or breast carcinoma in men (Hikma label)
  • Women who are pregnant — virilisation of the female fetus; the IM product's only indication in women is palliation of inoperable mammary cancer (label)
  • Serious cardiac, hepatic or renal disease — fluid retention and edema risk (label)
  • Known hypersensitivity to the drug, sesame oil or chlorobutanol (label)
  • Uncontrolled hypertension — Xyosted section 5.4 states it is not recommended (label)
Interactions
  • Oral anticoagulants (warfarin)Androgens increase sensitivity; the anticoagulant dose may need reduction (label)
  • Insulin and other antidiabetic drugsAndrogens may lower blood glucose and reduce insulin requirements (label)
  • OxyphenbutazoneSerum oxyphenbutazone levels may rise with concurrent androgens (label)
  • Thyroid function testsAndrogens lower thyroxine-binding globulin, reducing total T4 while free hormone stays normal (label)

Timeline commonly reported

  1. Hours 6–168 (SC)

    After a weekly Xyosted dose the label reports a median time to peak of 11.9 hours, with a wide range of 5.8 to 168.7 hours.

  2. Week 6 (SC)

    Steady state is reached by week 6 on weekly SC dosing per the Xyosted label; dose adjustment is based on a trough drawn 7 days after a dose at that point.

  3. Weeks 2–4 (IM)

    The IM label doses every 2–4 weeks; the textbook castor-oil figure of ~4.5 days half-life and 8.5 days mean residence time implies large peak-to-trough swings over that interval.

  4. Weeks to months

    Downstream effects (libido, mood, body composition, erythropoiesis, bone) follow the testosterone timeline, not the ester's — see the testosterone profile.

FAQ

Is testosterone enanthate a peptide?

No. It is testosterone esterified with heptanoic acid — a straight seven-carbon chain on the 17β-hydroxyl — giving C26H40O3, 400.6 g/mol. It is a reference entry so the parent testosterone page can compare esters; the index does not track enanthate products or prices.

What is the half-life of testosterone enanthate?

No US label states one. The only route-specific primary numbers are from the Xyosted sponsor's single-dose SC study NCT02233751 in 12 healthy men: total testosterone half-life 131.75 h (~5.5 days) at 200 mg and 261.73 h (~10.9 days) at 50 mg. The widely quoted ~4.5 days for IM injection comes from a textbook table for a castor-oil preparation, not from a primary paper, so we show it in the text only.

Why is the half-life longer at a lower dose?

Because these are apparent, absorption-limited half-lives. Testosterone itself clears in minutes; the curve's tail tracks release from the oil depot plus, in healthy men, their own endogenous baseline. At 50 mg the small exogenous increment sits close to that baseline, stretching the fitted terminal phase — a sign of flip-flop kinetics, not a property of the molecule.

Is there a subcutaneous enanthate product?

Yes — Xyosted (Antares Pharma), a 50, 75 or 100 mg per 0.5 mL single-dose autoinjector in sesame oil for once-weekly abdominal SC injection, approved as NDA 209863 on 2018-09-28. It is the only FDA-approved subcutaneous testosterone ester.

What oil is enanthate in?

Sesame oil in both US products. The Hikma IM generic is 200 mg/mL in sesame oil with 5 mg/mL chlorobutanol as preservative; Xyosted lists sesame oil as its only inactive ingredient. Cypionate uses cottonseed oil and Aveed castor oil, which matters for oil allergies.

Sources

Starting references for the library summary. These are not dosing instructions or medical advice.

For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.